Patent ID: 8501757

Claim:
A compound, or a pharmaceutically acceptable salt thereof, having a structure represented by a formula: wherein A is CR 2 or N; wherein L is O or NR 7 , wherein R 1 has from 1 to 10 carbons and is selected from phenyl substituted with 1-3 of R 9 , wherein at least one R 9 is meta substituted; 2-pyridinyl substituted with 0-3 of R 9 ; and thiazole substituted with 0-2 of R 9 ; wherein R 2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, amino, hydroxyl, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ; wherein R 3 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, CN, SO 2 R 8 , and COR 8 ; wherein R 4 and R 5 are independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, amino, hydroxyl, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , or COR 8 ; wherein R 6 is selected from hydrogen, halogen, CN, C1-C4 alkyl, C1-C4 haloalkyl, C3-C4 cycloalkyl, and C3-C4 halocycloalkyl; wherein each of R 6a , R 6b , and R 6c is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, amino, hydroxyl, alkylamino, dialkylamino, CN, SO 2 R 8 , and COR 8 ; wherein R 7 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl; wherein R 8 is alkyl, cycloalkyl, amino, alkylamino, or dialkylamino; and wherein each R 9 , when present, is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, alkylamino, dialkylamino, NO 2 , CN, SO 2 R 8 , and COR 8 ; wherein the compound exhibits partial or total inhibition of mGluR5 response to glutamate as a decrease in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound.